CAMBRIDGE, U.K.—Translational genomics company Horizon Discovery announced in mid-December a non-exclusive commercial agreement with OSI Pharmaceuticals under which OSI will evaluate nine of Horizon's X-MAN cell lines and matched cells with normal genetic backgrounds for 12 months. Financial terms of the agreement were not disclosed.

OSI wants to characterize the cell lines for the testing of both known and internally developed compounds directed at genotypes of interest. In addition, the parties will collaborate to generate new data in areas of mutual research interest. OSI will share key data-sets during the course of this year.

The X-MAN lines are cancer-related isogenic human cell lines developed to aid in drug discovery and assess treatments in clinical trials. DDN